- Home
- OPRT vs ALMS Comparison
OPRT vs ALMS Comparison
Compare OPRT & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- ALMS
- Stock Information
- Founded
- OPRT 2005
- ALMS 2021
- Country
- OPRT United States
- ALMS United States
- Employees
- OPRT N/A
- ALMS N/A
- Industry
- OPRT Finance: Consumer Services
- ALMS
- Sector
- OPRT Finance
- ALMS
- Exchange
- OPRT Nasdaq
- ALMS NYSE
- Market Cap
- OPRT 221.5M
- ALMS 260.6M
- IPO Year
- OPRT 2019
- ALMS 2024
- Fundamental
- Price
- OPRT $5.49
- ALMS $5.82
- Analyst Decision
- OPRT Buy
- ALMS Strong Buy
- Analyst Count
- OPRT 2
- ALMS 7
- Target Price
- OPRT $8.00
- ALMS $28.17
- AVG Volume (30 Days)
- OPRT 548.6K
- ALMS 1.2M
- Earning Date
- OPRT 05-08-2025
- ALMS 05-15-2025
- Dividend Yield
- OPRT N/A
- ALMS N/A
- EPS Growth
- OPRT N/A
- ALMS N/A
- EPS
- OPRT N/A
- ALMS N/A
- Revenue
- OPRT $763,617,000.00
- ALMS N/A
- Revenue This Year
- OPRT $28.45
- ALMS N/A
- Revenue Next Year
- OPRT $9.19
- ALMS N/A
- P/E Ratio
- OPRT N/A
- ALMS N/A
- Revenue Growth
- OPRT N/A
- ALMS N/A
- 52 Week Low
- OPRT $2.05
- ALMS $3.18
- 52 Week High
- OPRT $9.25
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- OPRT 43.63
- ALMS N/A
- Support Level
- OPRT $5.50
- ALMS N/A
- Resistance Level
- OPRT $6.11
- ALMS N/A
- Average True Range (ATR)
- OPRT 0.40
- ALMS 0.00
- MACD
- OPRT -0.07
- ALMS 0.00
- Stochastic Oscillator
- OPRT 18.59
- ALMS 0.00
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.